One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic

Ping Zhou1, Xun Ma1, Lakshmanan Iyer2

  • 1Tufts Medical Center, Boston, MA; and.

Blood
|April 12, 2014
PubMed

Insights

Short interfering RNA (siRNA) targeting lambda light chains offers a novel therapy for systemic light-chain amyloidosis. This approach reduces pathological lambda light chain production and induces apoptosis in plasma cells.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Systemic light-chain amyloidosis is caused by abnormal lambda light chains from clonal plasma cells, leading to organ damage and mortality.
  • Current treatments for light-chain amyloidosis have limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To develop and evaluate a novel therapeutic approach using short interfering RNA (siRNA) to target and reduce pathological lambda light chain production.
  • To investigate the effects of siRNA-mediated lambda light chain reduction on plasma cells and the unfolded protein response.

Main Methods:

  • Development of a pool of siRNA targeting the constant region of lambda light chains.
  • Assessment of siRNA efficacy in reducing lambda light chain production and secretion in human plasma cells.
  • Analysis of the unfolded protein response and endoplasmic reticulum stress markers in response to siRNA treatment.
  • Evaluation of apoptosis induction in plasma cells producing intact immunoglobulin G (IgG) lambda antibodies.

Main Results:

  • The developed siRNA pool substantially and promptly reduced lambda light chain production and secretion by human plasma cells.
  • In cells producing intact IgG lambda antibodies, siRNA treatment led to reduced antibody secretion and activation of all three branches of the unfolded protein response.
  • Accumulation of unpaired IgG heavy chains in the endoplasmic reticulum triggered an ER stress response, leading to terminal apoptosis mediated by NOXA.

Conclusions:

  • A pool of siRNA targeting lambda light chains is a promising therapeutic strategy for systemic light-chain amyloidosis.
  • This siRNA therapy effectively reduces pathological lambda light chain production and induces apoptosis in malignant plasma cells.
  • The findings highlight the potential of targeting lambda light chains to treat light-chain amyloidosis and related plasma cell disorders.

Related Concept Videos

Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.2K
Directing Proteins to the Rough Endoplasmic Reticulum01:34

Directing Proteins to the Rough Endoplasmic Reticulum

The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...
12.0K
Stringent Response in E. coli01:23

Stringent Response in E. coli

Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
528
The Unfolded Protein Response01:37

The Unfolded Protein Response

The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.6K
Post-translational Translocation of Proteins to the RER01:27

Post-translational Translocation of Proteins to the RER

A sizable fraction of proteins destined for ER are first synthesized in the cell cytosol and then transported across the ER membrane–a process called post-translational translocation. Similar to cotranslationally translocated proteins, these proteins also use the Sec translocon complex to enter the ER lumen.
Targeting proteins to the ER
Hsp40 and Hsp70 chaperone molecules bind the translated proteins in the cytosol to prevent their folding. The chaperone binding helps to keep the signal...
5.6K
Cotranslational Protein Translocation01:20

Cotranslational Protein Translocation

Translocation of proteins across membranes is an ancient process that occurs even in bacteria and archaebacteria. In fact, the components of the translocation machinery are still conserved between prokaryotes and eukaryotes.
Sec61 channel partners for cotranslational translocation
During cotranslational translocation, the Sec61 channel partners with the signal recognition particle (SRP), the signal recognition particle receptor (SR), and the ribosomes to transport the nascent polypeptide chain...
8.3K